[go: up one dir, main page]

ES537257A0 - Un procedimiento de inmunoensayo - Google Patents

Un procedimiento de inmunoensayo

Info

Publication number
ES537257A0
ES537257A0 ES537257A ES537257A ES537257A0 ES 537257 A0 ES537257 A0 ES 537257A0 ES 537257 A ES537257 A ES 537257A ES 537257 A ES537257 A ES 537257A ES 537257 A0 ES537257 A0 ES 537257A0
Authority
ES
Spain
Prior art keywords
assay procedure
immuno assay
immuno
procedure
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES537257A
Other languages
English (en)
Other versions
ES8606655A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES537257A0 publication Critical patent/ES537257A0/es
Publication of ES8606655A1 publication Critical patent/ES8606655A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES537257A 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo Expired ES8606655A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES537257A0 true ES537257A0 (es) 1986-04-01
ES8606655A1 ES8606655A1 (es) 1986-04-01

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533931A Expired ES8506091A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533930A Granted ES533930A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533931A Expired ES8506091A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533930A Granted ES533930A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES8504461A1 (es)
FI (1) FI834529A0 (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1214123A (en) * 1983-01-20 1986-11-18 Masashi Matsui Cell lines for use in the preparation of hybridoma cells
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
ATE64622T1 (de) * 1984-04-23 1991-07-15 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
JP2635343B2 (ja) 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
ES2058199T3 (es) * 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
CA2075927A1 (en) * 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JP3431140B2 (ja) * 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
AU741338B2 (en) * 1996-09-20 2001-11-29 Bristol-Myers Squibb Company Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
EP3138832A1 (en) 2004-03-16 2017-03-08 Temple University - Of The Commonwealth System of Higher Education Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
PL1912671T3 (pl) 2005-07-18 2018-02-28 Seattle Genetics, Inc. Koniugaty beta-glukuronid-linker-lek
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
ES2374330T3 (es) 2007-01-22 2012-02-15 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos.
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
US10227407B2 (en) 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
CA2960899C (en) 2014-09-17 2021-08-17 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3600443A1 (en) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CA3110096A1 (en) * 2018-08-30 2020-03-05 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cells for treating solid tumor
US20220409734A1 (en) 2019-05-10 2022-12-29 Yutaka Nishimoto Antibody drug conjugates
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
IT1219778B (it) 1990-05-24
GB2128631B (en) 1987-02-25
ES8604424A1 (es) 1986-02-01
ATA901883A (de) 1991-10-15
CA1213229A (en) 1986-10-28
IT8320548A0 (it) 1983-04-12
ES521370A0 (es) 1985-04-16
EP0105360A4 (en) 1986-07-08
ES533931A0 (es) 1985-06-16
EP0105360A1 (en) 1984-04-18
JPS6312276A (ja) 1988-01-19
GB8530310D0 (en) 1986-01-22
FI834529A (fi) 1983-12-09
GB2167086A (en) 1986-05-21
ES8607386A1 (es) 1986-05-16
ES538727A0 (es) 1986-02-01
GB2167086B (en) 1987-03-04
GB2169921B (en) 1987-03-04
GB8332646D0 (en) 1984-01-11
ES545247A0 (es) 1986-05-16
ES8504461A1 (es) 1985-04-16
AU1555983A (en) 1983-11-04
ES8603080A1 (es) 1985-12-01
GB8530308D0 (en) 1986-01-22
CH672796A5 (es) 1989-12-29
GB2128631A (en) 1984-05-02
GB2168998A (en) 1986-07-02
ES527963A0 (es) 1985-02-16
ES533930A0 (es) 1985-12-01
ES8506091A1 (es) 1985-06-16
ES8503441A1 (es) 1985-02-16
JPH0753119B2 (ja) 1995-06-07
AU550486B2 (en) 1986-03-20
GB2168998B (en) 1987-03-04
AT394577B (de) 1992-05-11
GB2169921A (en) 1986-07-23
JP2562002B2 (ja) 1996-12-11
JPH0753600A (ja) 1995-02-28
FI834529A0 (fi) 1983-12-09
WO1983003679A1 (en) 1983-10-27
GB8530309D0 (en) 1986-01-22
ES8606655A1 (es) 1986-04-01

Similar Documents

Publication Publication Date Title
ES527963A0 (es) Un procedimiento de inmunoensayo
BR8300936A (pt) Pinca de ligacao
DK52483D0 (da) Immunoassay
DK320783A (da) Klaebemiddel
ES524460A0 (es) Un metodo de inmunoensayo.
DK606183D0 (da) Stikforbindelse
FI840305A0 (fi) Demolerande produkt
FI823313A0 (fi) Accelerator foer en skakanordning
DK453283D0 (da) Forbindelser
FI832251L (fi) Reningsfoerfarande foer soetningsloesning
ES527737A0 (es) Procedimiento de preparacion de dinucleosidos-monofosfatos
ES525995A0 (es) Procedimiento de obtencion de piridopirimidinonas
ES519779A0 (es) Prensa-recogedora de sarmientos.
FI832971A0 (fi) Under vaermepaoverkan krympande foerbindelsemuff
FR2537351B1 (fr) Reglette de raccordement
ATA286582A (de) Testgeschoss
BR8205287A (pt) Acelerador de percussor
BR8202114A (pt) Cacada de bufalos
BR8202758A (pt) Amolador de facas
AR227230A1 (es) Un corpino mejorado
RO83994A2 (ro) Ciocan de abataj
FI821363L (fi) Test foer glykosilerade hemoglobiner
ATE34467T1 (de) Testverfahren.
BR8307464A (pt) Conjunto de acoplamento rapido
BR8204268A (pt) Registro de gas

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401